300 related articles for article (PubMed ID: 18072261)
1. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
[TBL] [Abstract][Full Text] [Related]
2. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
4. Editorial comment on: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
Montironi R
Eur Urol; 2007 Sep; 52(3):768. PubMed ID: 17240042
[No Abstract] [Full Text] [Related]
5. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
[TBL] [Abstract][Full Text] [Related]
6. Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections.
Castellini P; Montironi MA; Zizzi A; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Paone N; Montironi R
Hum Pathol; 2014 Apr; 45(4):745-52. PubMed ID: 24565208
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential.
Barbisan F; Mazzucchelli R; Santinelli A; Stramazzotti D; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Int J Immunopathol Pharmacol; 2008; 21(3):615-23. PubMed ID: 18831929
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of fibroblast growth factor receptor 3 and epidermal growth factor receptors, in association with Raf-1, in urothelial dysplasia and carcinoma in situ after the Chernobyl accident.
Romanenko AM; Morimura K; Kinoshita A; Wanibuchi H; Takahashi S; Zaparin WK; Vinnichenko WI; Vozianov AF; Fukushima S
Cancer Sci; 2006 Nov; 97(11):1168-74. PubMed ID: 16965395
[TBL] [Abstract][Full Text] [Related]
10. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
[TBL] [Abstract][Full Text] [Related]
11. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
12. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
Yin H; Leong AS
Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
[TBL] [Abstract][Full Text] [Related]
13. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
[TBL] [Abstract][Full Text] [Related]
14. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma.
Mai KT; Elmontaser G; Perkins DG; Yazdi HM; Stinson WA; Thijssen A
BJU Int; 2004 Sep; 94(4):544-7. PubMed ID: 15329109
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
Mallofré C; Castillo M; Morente V; Solé M
Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
[TBL] [Abstract][Full Text] [Related]
17. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
18. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.
Harnden P; Mahmood N; Southgate J
Lancet; 1999 Mar; 353(9157):974-7. PubMed ID: 10459907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
